ClinicalTrials.gg
RecruitingNCT06556407RDN-HDUpdated Sep 26, 2025

Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis

An interventional study of renal denervation in Treatment Resistant Hypertension and Chronic Hemodialysis, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2024, registered Aug 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.

Planned enrollment
8th of 11
12 · median 28
Started
2024
the only one that year
No phase
6 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 6 with no phase, and was the 12th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, or all of them as a file.
02

Study summary

The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.

Read the detailed description

Patients with end-stage renal disease (ESRD) and hemodialysis have a very high risk for cardiovascular events and a very high cardiovascular mortality. Uncontrolled treatment resistant hypertension (TRH) is an important factor driving this very high cardiovascular event risk. Clinical and experimental studies have clearly shown that sympathetic nerve activity is increased in patients with chronic kidney disease (CKD) and substantially aggravates the progression of CKD. In patients with ESRD and chronic hemodialysis bilateral nephrectomy reduced increased sympathetic nerve activity. Interestingly, kidney transplantation did not normalize peripheral sympathetic activity unless the native kidneys were removed. Thus, afferent sensory nerve signaling from the diseased kidneys to the central nervous system is an important pathophysiologic mechanism in CKD leading to sympathetic overactivity and hypertension. Clinical studies have demonstrated that invasive, catheter-based renal denervation (RDN) decreases the sympathetic nerve activity in the whole body and in particular in the kidneys

03

Conditions studied

  • Treatment Resistant Hypertension
  • Chronic Hemodialysis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg
  • end-stage renal disease on chronic hemodialysis
  • Stable hemodialysis regime for at least 3 months based on the decision of the treating physician
  • Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks.
  • Individual is ≥ 18 years of age, male and female patients are included.

Exclusion criteria

Exclusion Criteria:

  • Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient
  • Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement
  • Prior renal denervation procedure
  • Anatomic or functional solitary kidney, kidney transplantation
  • Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements
  • Endocrine hypertension other than obstructive sleep apnea
  • Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit
  • Acute episode of systemic and renal disease requiring uptitration of any drug regimen within the last 3 months
  • Subject is pregnant, nursing, or intends to become pregnant
  • Enrollment in another interventional research protocol.
  • Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    Treatment

    Intervention: Renal denervation

    Device: renal denervation

Interventions

  • Devicerenal denervation

    ultrasound based renal denervation

06

What researchers measure

Primary outcomes

  1. Safety endpoints and adverse effects

    A major combined safety endpoint is the incidence of any major adverse events (MAE) through the 6 months FU

    Time frame: during 6 months post-procedure

  2. Change in 24-h ambulatory systolic blood pressure between baseline and 3 months post-procedure

    Time frame: baseline and 3 months post-procedure

Secondary outcomes

  1. Change in 24-h ambulatory systolic blood pressure between baseline and 6 months post-procedure

    Time frame: between baseline and 6 months post-procedure.

  2. Change in 24-h ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure

    Time frame: baseline and 3, 6 months post-procedure.

  3. Change in office (attended) systolic and diastolic blood pressure between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

  4. Change in systolic and diastolic home blood pressure between baseline and 3, 6 months post-procedure.

    Time frame: between baseline and 3, 6 months post-procedure

  5. Number of antihypertensive drugs, doses, classes at 3, 6 months post-procedure compared to baseline.

    Time frame: at 3, 6 months post-procedure compared to baseline.

  6. Change in bio-impedance parameters between baseline and 3, 6 months post-procedure to assess the volume status.

    Time frame: between baseline and 3, 6 months post-procedure

  7. Change in central systolic and diastolic blood pressure, central pulse pressure and pulse wave velocity between baseline and 3,6 months post procedure

    Time frame: between baseline and 3,6 months post procedure

  8. Change in retinal arteriolar wall to lumen ratio between baseline and 3,6 months post procedure

    Time frame: between baseline and 3,6 months post procedure

  9. Change in average daytime/night-time ambulatory systolic blood pressure between baseline and 3, 6 months post-procedure.

    Time frame: between baseline and 3, 6 months post-procedure.

  10. Change in average daytime/night-time ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

  11. Change in office (attended) and ambulatory heart rate between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

  12. Changes in dipper/non-dipper patterns between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

  13. Change in retinal arterial remodeling between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

  14. Change in retinal capillary density between baseline and 3, 6 months post-procedure

    Time frame: between baseline and 3, 6 months post-procedure

07

Study locations

1 of 1 sites recruiting
  • Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension
    Erlangen, Bavaria 91054, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 16, 2024
StartActual
Mar 4, 2024
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06556407
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Mar 4, 2024
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 26, 2025

Study contacts

Agnes Bosch, MD
Contact
agnes.bosch@uk-erlangen.de
+49 9131 8536207
Roland E. Schmieder, MD
Contact
roland.schmieder@uk-erlangen.de
+499131 8536207

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion